Please upgrade your browser.
Argos is developing a therapy to treat metastatic renal cell carcinoma (mRCC) and hit the enrollment goal of 450 randomized patients. This is a Phase 3 trial, meaning it is one of the last major steps a drug developer takes before submitting an application with the U.S. Food and Drug Administration.
The 13-year total for “Lift for Life” is now more than $1.12 million. More than 100 members of the Nittany Lion football team participated in Saturday's Lift For Life.
Patients benefit twice from the new technique: during the operation itself, the risk of bleeding and complications is lower. In the long term, renal function is preserved and there are no long-term consequences of renal impairment.
Project Title: "Interrogation of the Sorbitol Pathway in VHL-Independent HIF driven Renal Cell Carcinomas"
Little is known about the biological behavior of Xp11.2 translocation renal cell carcinomas (RCCs) as few clinical studies have been performed using a large sample size.
Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma
The renin-angiotensin system may play a role in carcinogenesis. The purpose of this study was to evaluate the impact of angiotensin system inhibitors (ASI) on outcomes in metastatic renal cell carcinoma (mRCC) patients treated in the targeted therapy era.
The event will include the Penn State offense facing the defense in a series of competitions to benefit the Kidney Cancer Association.
Title Phase II study of oral PRednisone 5 mg bid plus EVerolimus in patients with metastatic renal cell cancer after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitor (PREV study).
The infographic displays the official ribbon colors of various diseases and matches them with awareness months.
A new study from the Mayo Clinic hints at a promising treatment for late-stage cancer patients—but a real breakthrough could be years away.
|Powered by NeonCRM|